Skip directly to content

Minimize RSR Award Detail

Research Spending & Results

Award Detail

Awardee:KANSAS STATE UNIVERSITY
Doing Business As Name:Kansas State University
PD/PI:
  • Stefan H Bossmann
  • (785) 532-6817
  • sbossman@ksu.edu
Co-PD(s)/co-PI(s):
  • Lawrence Sowers
  • Massoud Motamedi
  • Michael P Sheetz
  • Bala Natarajan
Award Date:09/10/2019
Estimated Total Award Amount: $ 2,000,000
Funds Obligated to Date: $ 2,000,000
  • FY 2019=$2,000,000
Start Date:01/01/2020
End Date:12/31/2023
Transaction Type:Grant
Agency:NSF
Awarding Agency Code:4900
Funding Agency Code:4900
CFDA Number:47.041
Primary Program Source:040100 NSF RESEARCH & RELATED ACTIVIT
Award Title or Description:EFRI CEE: Opening the Gates of Apoptosis in Cancer
Federal Award ID Number:1933321
DUNS ID:929773554
Parent DUNS ID:041146432
Program:EFRI Research Projects
Program Officer:
  • Garie Fordyce
  • (703) 292-8300
  • gfordyce@nsf.gov

Awardee Location

Street:2 FAIRCHILD HALL
City:Manhattan
State:KS
ZIP:66506-1100
County:Manhattan
Country:US
Awardee Cong. District:01

Primary Place of Performance

Organization Name:Kansas State University
Street:2 Fairchild Hall
City:Manhattan
State:KS
ZIP:66506-1100
County:Manhattan
Country:US
Cong. District:01

Abstract at Time of Award

Glioblastoma (GBM) is the most common and most aggressive adult primary brain tumor. GBM is known for the patient?s poor survival of less than 16 months despite surgical resection, radiation, and/or chemotherapy. There is a growing awareness that the interaction of tumors with their microenvironment, together with metabolic factors, is responsible for altering gene expression patterns, which enable the tumor to adapt and escape tumor treatment.This collaborative research project aims to develop novel biophotonic methods to recognize genome-wide epigenetic mutations in GBM. This methodology will not only permit the early diagnosis of GBM, it will also lead to a combination of mechanic and metabolic stimuli, which will be able to restore apoptosis (= programmed cell death) in GBM and other solid tumors. This proposal has the following aims: 1: Development of Nanoscale Technologies for Visualization and Characterization of Chromatin Alteration Induced by Mechano-metabolic Cues; Aim 2: Chromatin Level Epigenetic Engineering; and Aim 3: A Deep Hybrid Learning Model to Recognize and Predict Mechano-metabolic Conditions for Introducing Programmed Cell Death in GBM.The development of a new toolbox for reprogramming of transformed cells will have implications that will reach far beyond glioblastoma. It will apply to virtually all diseases with epigenetic drivers, among them numerous cancers, neurodegenerative diseases, cardiovascular diseases, obesity and metabolic syndrome. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

For specific questions or comments about this information including the NSF Project Outcomes Report, contact us.